Giulia C. Kennedy, Ph.D.
Chief Scientific Officer and Chief Medical Officer
Giulia C. Kennedy is Chief Scientific and Medical Officer for Veracyte. Since joining the genomic diagnostics company in 2008, Dr. Kennedy has overseen the development of seven commercialized genomic tests that help inform diagnosis and treatment decisions in cancer and other diseases. The company’s tests are widely reimbursed and are setting new standards in genomic diagnostics by helping patients avoid unnecessary invasive procedures, speeding time to diagnosis and guiding next steps in patient care. Through Dr. Kennedy’s scientific leadership, Veracyte pushes the boundaries of what is possible in genomic diagnostics, including through the use of RNA whole-transcriptome sequencing and machine learning to develop tests that answer specific clinical questions. Prior to Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc.
Before that, she was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development. Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes. Dr. Kennedy serves on the board of directors for Astarte Medical, a privately held company that uses software and predictive analytics to improve preterm infant outcomes. She holds a Ph.D. degree in biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 60 articles in peer-reviewed scientific journals and is a co-inventor on more than 25 patents.